Показать сокращенную информацию
dc.contributor.author | Ramirez U. | |
dc.contributor.author | Nikonova A. | |
dc.contributor.author | Liu H. | |
dc.contributor.author | Pecherskaya A. | |
dc.contributor.author | Lawrence S. | |
dc.contributor.author | Serebriiskii I. | |
dc.contributor.author | Zhou Y. | |
dc.contributor.author | Robinson M. | |
dc.contributor.author | Einarson M. | |
dc.contributor.author | Golemis E. | |
dc.contributor.author | Jaffe E. | |
dc.date.accessioned | 2018-09-18T20:36:35Z | |
dc.date.available | 2018-09-18T20:36:35Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/141653 | |
dc.description.abstract | © Ramirez et al. 2015. Background: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration, which we identify as a potential target for drug discovery. Methods: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2. Results: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic cetuximab, guiding further chemical optimization. Conclusions: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target. | |
dc.subject | Epidermal growth factor receptor | |
dc.subject | Extracellular domain | |
dc.subject | Grb2 | |
dc.subject | Protein multimerization | |
dc.title | Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 1 | |
dc.relation.ispartofseries-volume | 15 | |
dc.collection | Публикации сотрудников КФУ | |
dc.source.id | SCOPUS-2015-15-1-SID84930666116 |